Topiramate Tablet, Film Coated
Product Images NDC 72789-004

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 72789-004). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

72789004 Label (72789004)

72789004 Label (72789004)
Label for Topiramate USP 100 mg film-coated tablets, containing 21 tablets per bottle. The label includes the PD-Rx Pharmaceuticals, Inc. logo and address in Oklahoma City, OK. It displays the National Drug Code (NDC) 72789-004-21 and lot number A21D36 with expiration date 01/2023. Instructions mention keeping out of reach of children and refer users to the package insert for dosage and storage details.*
FDA Label Image

Chemical-structure (Chemical Structure)

Chemical-structure (Chemical Structure)
Chemical structure diagram of Topiramate, showing its molecular composition with oxygen, sulfur, nitrogen atoms and various functional groups in a cyclic arrangement as commonly depicted for this active ingredient.*
FDA Label Image

Figure-1jpg (Figure 1)

Figure-1jpg (Figure 1)
A Kaplan-Meier curve showing cumulative rates for time to first seizure over 500 days. The graph compares Topiramate 50 mg/day (N=234) and Topiramate 400 mg/day (N=236), with time in days on the x-axis and cumulative seizure rate on the y-axis. A p-value of 0.0002 is displayed, indicating statistical significance between the groups.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A bar chart depicting changes from baseline to double-blind phase in average monthly migraine period rate (+SE) for placebo and Topiramate at doses of 50 mg/day, 100 mg/day, and 200 mg/day. Results are shown for two studies (Study 11 and Study 12) with significance annotations denoting p-values. Sample sizes for each group are indicated at the top.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.